Zymafos (palifosfamide)

News alerts, weekly reports and conference planners

Company:

Alaunos Therap

Drug class:

Bifunctional alkylating agent

Related drugs:

‹

ifosfamide (59)

›

3years

An in vitro cytotoxicity of glufosfamide in HepG2 cells relative to its nonconjugated counterpart. (PubMed, J Egypt Natl Canc Inst)

The current study reported for the first time cytotoxicity activity of glufosfamide in HepG2 cells in vitro. The obtained results confirmed the higher oncolytic activity of glufosfamide than its aglycone ifosfamide. The generated data warrants further elucidations by in vivo study.

3 years ago

Preclinical • Journal • IO biomarker

BCL2 (B-cell CLL/lymphoma 2) • CASP3 (Caspase 3) • CASP9 (Caspase 9)

BCL2 expression • CASP3 elevation

Zymafos (palifosfamide) • glufosfamide (D 19575)

over3years

SUNitinib and EVOfosfamide (TH-302) in systemic treatment-naïve patients with G1/G2 metastatic pancreatic neuroendocrine tumors, the GETNE-1408 trial. (PubMed, Oncologist)

Addition of hypoxia-activated prodrugs has been proposed as a potential mechanism to overcome tumor resistance to antiangiogenic agents. Sunitinib and evofosfamide, which were widely proposed as a potential synergistic option, showed modest efficacy in panNETs, reaching a median ORR of 17.6% and median PFS of 10.4 months. Treatment response does not correlate with the biomarkers analyzed. The high systemic toxicity, with 88.2% of patients discontinuing the treatment, makes this therapeutic approach unfeasible and encourages future research to overcome panNETs resistance to antiangiogenic agents with other therapies with a safer profile.

over 3 years ago

Clinical • Journal

PTEN (Phosphatase and tensin homolog) • ATRX (ATRX Chromatin Remodeler) • SETD2 (SET Domain Containing 2, Histone Lysine Methyltransferase) • DAXX (Death-domain associated protein)

PTEN mutation

sunitinib • evofosfamide (IMGS-101) • Zymafos (palifosfamide)